2025 annual financial data

Entrada Therapeutics 2025 Net margin

Entrada Therapeutics 2025 net margin with verified reported values.

Direct answer

Net margin was -565.48%.

Operating income was -155,998,000 USD and net income was -143,750,000 USD.
Operating cash flow was -128,512,000 USD.

Get free Entrada Therapeutics email updates.

Bullstory sends one daily email when new analysis or important company news is available.

Verified data

Revenue
25,421,000 USD
Operating income
-155,998,000 USD
Net income
-143,750,000 USD
Operating cash flow
-128,512,000 USD